CCL11 (Eotaxin-1) Levels Predict Long-Term Functional Outcomes in Patients Following Ischemic Stroke

Overview

Journal Transl Stroke Res

Publisher Springer

Date 2017 Jun 22

PMID 28634890

Citations 22

Authors

Meaghan Roy-OReilly

Rodney M Ritzel

Sarah E Conway

Ilene Staff

Gilbert Fortunato

Louise D McCullough

Affiliations

Soon will be listed here.

Abstract

Circulating levels of the pro-inflammatory cytokine C-C motif chemokine 11 (CCL11, also known as eotaxin-1) are increased in several animal models of neuroinflammation, including traumatic brain injury and Alzheimer's disease. Increased levels of CCL11 have also been linked to decreased neurogenesis in mice. We hypothesized that circulating CCL11 levels would increase following ischemic stroke in mice and humans, and that higher CCL11 levels would correlate with poor long-term recovery in patients. As predicted, circulating levels of CCL11 in both young and aged mice increased significantly 24 h after experimental stroke. However, ischemic stroke patients showed decreased CCL11 levels compared to controls 24 h after stroke. Interestingly, lower post-stroke CCL11 levels were predictive of increased stroke severity and independently predictive of poorer functional outcomes in patients 12 months after ischemic stroke. These results illustrate important differences in the peripheral inflammatory response to ischemic stroke between mice and human patients. In addition, it suggests CCL11 as a candidate biomarker for the prediction of acute and long-term functional outcomes in ischemic stroke patients.

Citing Articles

Chemokines play a role in nerve damage and neuroprotection in vascular dementia.

Ma J, Zhang M, Fu P, Yin X, Chen Z IBRO Neurosci Rep. 2024; 17:154-160.

PMID: 39206161 PMC: 11350449. DOI: 10.1016/j.ibneur.2024.08.002.

Gut Microbiota and Autism Spectrum Disorder: A Neuroinflammatory Mediated Mechanism of Pathogenesis?.

Zarimeidani F, Rahmati R, Mostafavi M, Darvishi M, Khodadadi S, Mohammadi M Inflammation. 2024; .

PMID: 39093342 DOI: 10.1007/s10753-024-02061-y.

Loss of Epitranscriptomic Modification N-Methyladenosine (mA) Reader YTHDF1 Exacerbates Ischemic Brain Injury in a Sexually Dimorphic Manner.

Chokkalla A, Arruri V, Mehta S, Vemuganti R Transl Stroke Res. 2024; .

PMID: 38869772 DOI: 10.1007/s12975-024-01267-4.

Circulating Chemokines and Short- and Long-Term Outcomes After Ischemic Stroke.

Klimiec-Moskal E, Koceniak P, Weglarczyk K, Slowik A, Siedlar M, Dziedzic T Mol Neurobiol. 2024; 62(1):421-428.

PMID: 38861234 PMC: 11711783. DOI: 10.1007/s12035-024-04279-1.

Blood-based therapies to combat neurodegenerative diseases.

Lee J, Lim M, Koh R, Tsen M, Chye S Metab Brain Dis. 2024; 39(5):985-1004.

PMID: 38842660 DOI: 10.1007/s11011-024-01368-x.

References

Targowski T, Jahnz-Rozyk K, Plusa T, Glodzinska-Wyszogrodzka E . Influence of age and gender on serum eotaxin concentration in healthy and allergic people. J Investig Allergol Clin Immunol. 2006; 15(4):277-82. View

Fryer A, Stein L, Nie Z, Curtis D, Evans C, Hodgson S . Neuronal eotaxin and the effects of CCR3 antagonist on airway hyperreactivity and M2 receptor dysfunction. J Clin Invest. 2005; 116(1):228-36. PMC: 1319219. DOI: 10.1172/JCI25423. View

Xia M, Qin S, Wu L, Mackay C, Hyman B . Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains. Am J Pathol. 1998; 153(1):31-7. PMC: 1852933. DOI: 10.1016/s0002-9440(10)65542-3. View

Manwani B, Friedler B, Verma R, Venna V, McCullough L, Liu F . Perfusion of ischemic brain in young and aged animals: a laser speckle flowmetry study. Stroke. 2013; 45(2):571-8. PMC: 3946827. DOI: 10.1161/STROKEAHA.113.002944. View

Shein S, Shellington D, Exo J, Jackson T, Wisniewski S, Jackson E . Hemorrhagic shock shifts the serum cytokine profile from pro- to anti-inflammatory after experimental traumatic brain injury in mice. J Neurotrauma. 2014; 31(16):1386-95. PMC: 4186809. DOI: 10.1089/neu.2013.2985. View

Adar T, Shteingart S, Ben Yaacov A, Bar-Gil Shitrit A, Goldin E . From airway inflammation to inflammatory bowel disease: eotaxin-1, a key regulator of intestinal inflammation. Clin Immunol. 2014; 153(1):199-208. DOI: 10.1016/j.clim.2014.04.012. View

Di Battista A, Rhind S, Hutchison M, Hassan S, Shiu M, Inaba K . Inflammatory cytokine and chemokine profiles are associated with patient outcome and the hyperadrenergic state following acute brain injury. J Neuroinflammation. 2016; 13:40. PMC: 4754875. DOI: 10.1186/s12974-016-0500-3. View

Huber A, Giles D, Segal B, Irani D . An emerging role for eotaxins in neurodegenerative disease. Clin Immunol. 2016; 189:29-33. DOI: 10.1016/j.clim.2016.09.010. View

Manwani B, Liu F, Xu Y, Persky R, Li J, McCullough L . Functional recovery in aging mice after experimental stroke. Brain Behav Immun. 2011; 25(8):1689-700. PMC: 3191237. DOI: 10.1016/j.bbi.2011.06.015. View

10.

Gerber B, Zanni M, Uguccioni M, Loetscher M, Mackay C, Pichler W . Functional expression of the eotaxin receptor CCR3 in T lymphocytes co-localizing with eosinophils. Curr Biol. 1998; 7(11):836-43. DOI: 10.1016/s0960-9822(06)00371-x. View

11.

Emanuele E, Falcone C, DAngelo A, Minoretti P, Buzzi M, Bertona M . Association of plasma eotaxin levels with the presence and extent of angiographic coronary artery disease. Atherosclerosis. 2005; 186(1):140-5. DOI: 10.1016/j.atherosclerosis.2005.07.002. View

12.

Kitaura M, Nakajima T, Imai T, Harada S, Combadiere C, Tiffany H . Molecular cloning of human eotaxin, an eosinophil-selective CC chemokine, and identification of a specific eosinophil eotaxin receptor, CC chemokine receptor 3. J Biol Chem. 1996; 271(13):7725-30. DOI: 10.1074/jbc.271.13.7725. View

13.

Chung K, Patel H, Fadlon E, Rousell J, Haddad E, Jose P . Induction of eotaxin expression and release from human airway smooth muscle cells by IL-1beta and TNFalpha: effects of IL-10 and corticosteroids. Br J Pharmacol. 1999; 127(5):1145-50. PMC: 1566131. DOI: 10.1038/sj.bjp.0702660. View

14.

Zschaler J, Schlorke D, Arnhold J . Differences in innate immune response between man and mouse. Crit Rev Immunol. 2014; 34(5):433-54. View

15.

De Paulis A, Annunziato F, Di Gioia L, Romagnani S, Carfora M, Beltrame C . Expression of the chemokine receptor CCR3 on human mast cells. Int Arch Allergy Immunol. 2001; 124(1-3):146-50. DOI: 10.1159/000053694. View

16.

Miyamasu M, Misaki Y, Yamaguchi M, Yamamoto K, Morita Y, Matsushima K . Regulation of human eotaxin generation by Th1-/Th2-derived cytokines. Int Arch Allergy Immunol. 2000; 122 Suppl 1:54-8. DOI: 10.1159/000053634. View

17.

Sallusto F, Mackay C, Lanzavecchia A . Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science. 1997; 277(5334):2005-7. DOI: 10.1126/science.277.5334.2005. View

18.

Villeda S, Luo J, Mosher K, Zou B, Britschgi M, Bieri G . The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature. 2011; 477(7362):90-4. PMC: 3170097. DOI: 10.1038/nature10357. View

19.

Garcia-Zepeda E, Rothenberg M, Ownbey R, Celestin J, Leder P, Luster A . Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med. 1996; 2(4):449-56. DOI: 10.1038/nm0496-449. View

20.

Mir A, Minguez M, Tatay J, Pascual I, Pena A, Sanchiz V . Elevated serum eotaxin levels in patients with inflammatory bowel disease. Am J Gastroenterol. 2002; 97(6):1452-7. DOI: 10.1111/j.1572-0241.2002.05687.x. View